{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:24:39Z","timestamp":1784690679671,"version":"3.55.0"},"reference-count":30,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"10","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2025,10,3]]},"DOI":"10.1167\/tvst.14.10.6","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:30:45Z","timestamp":1759494645000},"page":"6","source":"Crossref","is-referenced-by-count":1,"title":["Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes"],"prefix":"10.1167","volume":"14","author":[{"given":"Jenny","family":"Park","sequence":"first","affiliation":[{"name":"AbbVie, Clinical Pharmacology, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kazemi","sequence":"additional","affiliation":[{"name":"Independent Consultant, San Jose, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitalee","family":"Tamhane","sequence":"additional","affiliation":[{"name":"AbbVie, Clinical Pharmacology, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"AbbVie, Clinical Pharmacology, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"bib2","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2008.10.001","article-title":"Molecular pathology of age-related macular degeneration","volume":"28","author":"Ding","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1167\/iovs.15-16418","article-title":"Intraocular pharmacokinetics of aflibercept and vascular endothelial growth factor-A","volume":"56","author":"Celik","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40123-022-00532-9","article-title":"Pharmacokinetics of the port delivery system with ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration","volume":"11","author":"Wykoff","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s11095-010-0163-1","article-title":"Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model","volume":"27","author":"Missel","year":"2010","journal-title":"Pharm Res"},{"key":"bib10","article-title":"A nonlinear finite element model of the human eye to investigate ocular injuries from night vision goggles","author":"Power","journal-title":"Virginia Tech"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","article-title":"Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models","volume":"170","author":"Chowdhury","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/sj.mt.6300071","article-title":"Topoisomerase inhibition accelerates gene expression after adeno-associated virus-mediated gene transfer to the mammalian heart","volume":"15","author":"Prasad","year":"2007","journal-title":"Mol Ther"},{"key":"bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4028\/www.scientific.net\/DDF.326-328.452","article-title":"Measurement of the molecular mass dependence of the mass diffusion coefficient in protein aqueous solutions","volume":"326\u2013328","author":"Torres","year":"2012","journal-title":"Defect and Diffusion Forum"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol Pharm"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s11095-008-9691-3","article-title":"Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow","volume":"25","author":"Balachandran","year":"2008","journal-title":"Pharm Res"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0169-409X(01)00187-9","article-title":"Pharmacokinetic model for in vivo\/in vitro correlation of intravitreal drug delivery","volume":"52","author":"Tojo","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.3230","article-title":"Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene therapy","volume":"115","author":"Ford","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Review: Role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm Res"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpt.3228","article-title":"The US Food and Drug Administration's Model-Informed Drug Development Meeting Program: From Pilot to Pathway","volume":"116","author":"Madabushi","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"e0133968","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS One"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3928\/23258160-20210330-03","article-title":"Real-world treatment patterns in a population with neovascular AMD treated with anti-VEGF agents","volume":"52","author":"Urbano","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jcjo.2021.10.008","article-title":"Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis","volume":"58","author":"MacCumber","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"bib28","first-page":"253","article-title":"Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema","volume":"26","author":"Kiss","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"bib11","first-page":"567","article-title":"A comprehensive guide to toxicology in preclinical drug development","volume-title":"Chapter 24 - Safety Evaluation of Ocular Drugs, Academic Press","author":"Faqi","year":"2013"},{"key":"bib16","author":"LUCENTIS (ranibizumab injection)"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2810914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:30:46Z","timestamp":1759494646000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2810914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.14.10.6","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}